OKYO Pharma’s OK-101 Drug Phase 2 Trial now listed on ClinicalTrials.gov

(24/7 MARKET NEWS) – OKYO Pharma Limited (NASDAQ: OKYO) stated, this morning, that its planned Phase II trial evaluating the efficacy and safety of OK-101 in subjects with DED is posted on the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208).

OKYO is trading at $2.02, up $0.27 (+15.43%), on 780 thousand premarket shares traded.

Its 52-week trading range is $1.6101 to $7.00. Its premarket high is $3.08, but this may just be a repeat of its February 17 trading action, so scalping may be the play.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist